Table 4. Summary of studies investigating the safety and efficacy of SIRT.

Independent studies
Study	Total	CP	ECOG	PVTT	Extra-hepatic involvement	Tumor characteristic	Safety and Efficacy
Kulik et al. 2008 [102]	n=108	A/B/C=54/27/1	0–2	37	13	Unresectable Intermediate-advanced	PR: WHO 42.2%, EASL 70% No treatment-related complications or deaths
Mazzaferro et al. 2013 [103]	n=52	A-B7	0–1	35	None	Intermediate-advanced	mOS=15 months ORR=40.4% TTP=11 months
Salem et al. 2010 [104]	n=291	A=131 B=152 C=8	0–2	125	46	All stages	ORR: WHO=42%, EASL=57% TTP=7.9 months mOS: CP A/B=17.2/7.7 months
Sangro et al. 2011 [105]	n=325	A=268 B=57	0–3	76	30	All stages	mOS=12.8 months (BCLC A, B, C=24.4, 16.9, 10 months)
Lewandowski et al. 2018 [106]	n=70	A	NA	0	0	Early-stage PVTT: absent	RR 6-months=EASL (86%), WHO (49%) TTP=2.4 years
Meta-analysis
Lobo et al.[107] 2016	n=553 (5 comparative studies, with quality assessed by the STROBE criteria)			CR and PR: No significant difference (vs cTACE) Vs. cTACE: Less post-treatment pain, more subjective fatigue; no difference in nausea, vomiting, fever, or other complications
Massani et al. 2016 [108]	n=1431 (8 studies)			OS: No significant difference (vs. TACE) Adverse events: Less than TACE
Yang et al. 2018 [96]	n=1652 (11 studies, including 2 RCTs)			OS: Increased 2-year OS OR: Better (vs. TACE, mRECIST criteria) Adverse events: Less than cTACE
Gardini et al. 2018 [109]	n=97 (3 RCTs)			OS, PFS: No significant difference at 1-year Bridging: Higher proportion underwent transplant

c-TACE: Conventional TACE; CP: Child-Pugh; DEB-TACE: Drug-eluting bead TACE; ECOG: Eastern Co-operative Oncology Group performance status; ORR: Objective response rates; OS: Overall survival; PVTT: Portal vein tumor thrombosis; RCT: Randomized controlled trials; RR: Response rate: SIRT: Selective internal radiation therapy; TTP: Time to progression; STROBE: Strengthening the Reporting of Observational studies in Epidemiology criteria